Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy IN8bio stock
Learn how to easily invest in IN8bio stock.
In8bio Inc is a biotechnology business based in the US. IN8bio shares (INAB) are listed on the NASDAQ and all prices are listed in US Dollars. IN8bio employs 19 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in IN8bio
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – INAB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
IN8bio stock price (NASDAQ: INAB)Use our graph to track the performance of INAB stocks over time.
IN8bio shares at a glance
|Latest market close||$1.78|
|52-week range||$1.75 - $9.42|
|50-day moving average||$2.27|
|200-day moving average||$3.19|
|Wall St. target price||$11.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.29|
Buy IN8bio shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy IN8bio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
IN8bio price performance over time
|1 week (2022-09-20)||-23.28%|
|1 month (2022-08-26)||-9.18%|
|3 months (2022-06-28)||-24.99%|
|6 months (2022-03-28)||-45.23%|
|1 year (2021-09-28)||-75.68%|
|2 years (2020-09-24)||N/A|
|3 years (2019-09-24)||N/A|
|5 years (2017-09-24)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-58.09%|
|Return on equity TTM||-112.18%|
|Market capitalisation||$48.8 million|
TTM: trailing 12 months
IN8bio share dividends
We're not expecting IN8bio to pay a dividend over the next 12 months.
You may also wish to consider:
- BioNTech (BNTX.US) (1.33% forward annual dividend yield)
IN8bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.
IN8bio in the news
IN8bio to Present at Cantor Oncology & HemOnc Conference
IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400
IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
Frequently asked questionsWhat percentage of IN8bio is owned by insiders or institutions?
Currently 25.748% of IN8bio shares are held by insiders and 14.096% by institutions. How many people work for IN8bio?
Latest data suggests 19 work at IN8bio. When does the fiscal year end for IN8bio?
IN8bio's fiscal year ends in December. Where is IN8bio based?
IN8bio's address is: 350 5th Avenue, New York, NY, United States, 10118 What is IN8bio's ISIN number?
IN8bio's international securities identification number is: US45674E1091
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert